知镜 Cognispect · 医学文献与研究工作台

CRISPR Technology: From Bench to Bedside Applications.

Ma X, Li L, Sun Y.
MedComm · 2026-11-09 · PMID 43011237

文献摘要

CRISPR-Cas genome editing represents one of the most transformative advances in modern molecular biology, enabling programmable site-specific genetic modification that has revolutionized functional genomics and precision therapeutic development. Beyond canonical Cas9 nucleases, the CRISPR toolkit has diversified into precision base editors, prime editors, CRISPR-associated transposases, and Cas12/Cas13 RNA-targeting effectors, each with distinct mechanistic properties. Clinically, ex vivo CRISPR therapies for hemoglobinopathies have secured regulatory approval, while base editing, prime editing, and in vivo Chimeric Antigen Receptor (CAR)-T candidates are advancing through trials for a broad spectrum of hematologic, oncologic, and rare genetic disorders. However, existing reviews largely address technical innovation or clinical translation in isolation, lacking a holistic, up-to-date synthesis of the full bench-to-bedside trajectory of CRISPR technology. This review systematically dissects the molecular mechanisms, advantages, and limitations of core CRISPR editing platforms; summarizes pivotal clinical data across hemoglobinopathies, CAR-T immunotherapy, muscular dystrophy, cystic fibrosis, cardiometabolic diseases and rare monogenic diseases; evaluates delivery systems including lipid nanoparticles and viral vectors; and discusses key translational barriers such as off-target genotoxicity and immunogenicity alongside emerging optimization strategies. This work provides a holistic bench-to-bedside framework for CRISPR research, offering critical insights to advance next-generation precision genetic medicine.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。